Présentation de l'entreprise
Fulgent Genetics, Inc. operates as a provider of clinical diagnostic and therapeutic development solutions, serving physicians and patients across the United States and international markets through its extensive network of laboratories. The company functions within the healthcare sector, specifically targeting the diagnostics and research industry, which positions it as a key player in molecular diagnostic testing, genetic testing, and anatomic pathology laboratory services. This entity maintains a significant operational scale, with a total market capitalization of $494.38M, annual revenue of $322.67M, and a workforce comprising 1315 employees. These valuation and revenue figures indicate that Fulgent Genetics holds a substantial market presence within the specialized diagnostic space, reflecting a mature business model that has achieved multi-hundred-million-dollar revenue streams while maintaining a mid-cap valuation that suggests room for expansion or consolidation in the broader healthcare diagnostics landscape.
Santé financière
The company reported a trailing twelve-month revenue of $322.67M, yet this generated a net income of -$60,513,000 and an EBITDA of -$65,049,000, revealing a cost structure where operating expenses significantly exceed gross profits before interest and taxes. Despite generating substantial revenue, the negative net income indicates that the firm is currently operating at a loss, a common characteristic in capital-intensive diagnostic sectors during growth phases or due to high overhead costs. The free cash flow stands at -$121,573,376, which signifies that the company is consuming cash reserves to fund operations and potentially invest in infrastructure, thereby limiting immediate financial flexibility for aggressive shareholder returns. The margin profile presents a complex picture with a gross margin of 40.6%, suggesting efficient product pricing relative to direct costs, contrasted sharply by an operating margin of -41.2% and a profit margin of -18.8%, which highlight substantial inefficiencies in overhead management or high sales, general, and administrative expenses. On the balance sheet, the company holds $336.08M in cash against only $8.04M in debt, resulting in a debt-to-equity ratio of 0.73, which demonstrates a highly conservative financial posture with minimal leverage risk. This liquidity position is further reinforced by a current ratio of 6.48, indicating that the company possesses more than six times the current assets needed to cover its short-term liabilities, ensuring robust short-term solvency. Additionally, the return on equity is -5.5% and the return on assets is -4.6%, metrics that reflect the current inability of management to generate positive returns on the capital invested by shareholders or utilized in assets, consistent with the reported net losses.
Évaluation de la valorisation
The valuation metrics for Fulgent Genetics show a trailing P/E ratio that is effectively non-existent due to losses, while the forward P/E is listed as -10.66, implying that analysts do not expect immediate profitability in the near term. The price-to-book ratio is 0.44, indicating that the market values the company at less than half of its book value, which often suggests a market discount or a perception of high risk regarding future earnings potential. Alternative valuation metrics such as a price-to-sales ratio of 1.53 and an EV/EBITDA of -2.48 provide context for investors analyzing the stock without relying on earnings multiples, suggesting the market is pricing the company based on revenue generation and enterprise value rather than profitability. The stock has traded between a 52-week high of $31.04 and a 52-week low of $13.46, placing the current valuation within a range that reflects significant volatility over the past year. With a beta of 0.89, the stock exhibits price volatility that is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to high-beta technology or biotech peers.
Growth & Income
Fulgent Genetics demonstrated a year-over-year revenue growth of 9.3%, whereas earnings growth is marked as N/A due to the company's continued unprofitability, implying that revenue expansion is occurring without yet translating into bottom-line gains. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, indicating that earnings are currently being retained and reinvested into the business to support growth initiatives rather than being returned to shareholders. The absence of a dividend payout ratio of 0.0% confirms that the firm prioritizes capital allocation toward operational scaling and R&D over immediate income distribution to investors. Overall, the growth and income profile of Fulgent Genetics is characterized by solid single-digit revenue expansion coupled with a lack of current profitability and income distribution, positioning the stock as a pure growth play dependent on future margin improvement rather than current cash flow generation.